The absence of change in ALT, GGT, or validated liver fibrosis scores in most of the studies limits conclusions about direct hepatic benefits, yet it underscores the need for future trials incorporating liver-specific imaging or biomarkers to better clarify the hepatic versus systemic contributions of probiotics in post-bariatric patients. The gene discussed is GPT; the disease is Hepatic fibrosis.